Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
June 02 2016 - 4:00PM
Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today
announced that its Board of Directors has declared a quarterly cash
dividend payment on the Company's 10.50% Series E Convertible
Preferred Stock (the "Series E Preferred Stock").
The quarterly dividend on the Series E Preferred
Stock is payable on July 1, 2016 to holders of record at the close
of business on June 17, 2016.
The quarterly dividend payment on the Series E
Preferred Stock will be $0.65625 per share, which is equivalent to
an annualized 10.50% per share, based on the $25.00 per share
stated liquidation preference, accruing from April 1, 2016 through
June 30, 2016. The Series E Preferred Stock is listed on the NASDAQ
Capital Market and trades under the ticker symbol "PPHMP".
About Peregrine Pharmaceuticals,
Inc.Peregrine Pharmaceuticals, Inc. is a company focused
on continued revenue growth from its contract manufacturing
business and developing its novel immuno-oncology products.
The company is working to evaluate its lead immunotherapy
candidate, bavituximab, in combination with a range of novel
immuno-oncology (I-O) agents for the treatment of various
cancers. Peregrine’s in-house cGMP manufacturing capabilities
are provided through its wholly-owned subsidiary Avid Bioservices,
Inc. (www.avidbio.com), which provides development and
biomanufacturing services for both Peregrine and third-party
customers. For more information, please visit
www.peregrineinc.com.
Contacts:
Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avid Bioservices (NASDAQ:CDMO)
Historical Stock Chart
From Apr 2023 to Apr 2024